Key result
Dilated cardiomyopathy was associated with de novo expression of oncofetal glycosylated and ED-B+ fibronectin variants in the myocardium, which were absent in normal adult hearts.
Why the study?
Are oncofetal fibronectin molecular variants expressed in the myocardium of patients with dilated cardiomyopathy compared to normal hearts?
Population
10 patients with clinical criteria and histological diagnosis of dilated cardiomyopathy and 3 individuals…
Comparison
Immunohistochemistry and RNA in situ… vs Samples from individuals with normal hearts
Design
Case_series
Authors
Loading...
May represent a myocardial marker in dilated cardiomyopathy; hypothesis-generating and requires validation before clinical consideration.
Observational (n=13)
No
Are oncofetal fibronectin molecular variants expressed in the myocardium of patients with dilated cardiomyopathy compared to normal hearts?
Oncofetal fibronectin variants are newly expressed in the myocardium of patients with dilated cardiomyopathy, suggesting their potential as disease markers.
Gabler et al. (1996) conducted an observational in Dilated cardiomyopathy (DCM) (n=13). Right ventricular endomyocardial biopsy vs. Normal hearts was evaluated on Distribution of oncofetal FN variants in DCM hearts. Dilated cardiomyopathy was associated with de novo expression of oncofetal glycosylated and ED-B+ fibronectin variants in the myocardium, which were absent in normal adult hearts.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: